Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer


Creative Commons License

Bisgin A. , Kargi A., Yalcin A. D. , Aydin C., Ekinci D., Savas B., ...More

BMC CANCER, vol.12, 2012 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12
  • Publication Date: 2012
  • Doi Number: 10.1186/1471-2407-12-58
  • Title of Journal : BMC CANCER

Abstract

Background: Colorectal cancer is the third most common cancer and the third leading cause of cancer-related death. Bevacizumab is a humanized monoclonal antibody developed against vascular endothelial growth factor (VEGF) for the treatment of metastatic cancer. The parameters of RECIST (Response Evaluation Criteria for Solid Tumors) are not adequate to detect important treatment effects and response. Our goal was to evaluate the possibility of using sTRAIL (serum-soluble TNF-related apoptosis-inducing ligand) and VEGF as markers of treatment efficacy and prognosis in patients with metastatic colon cancer.